Interestingly the Abdx RNS included the following paragraph
Importantly, due to the utility of the score card used alongside the AbC-19TM test for these applications, Abingdon intends to make a supplementary product available, initially for research use only, in August which provides a semi-quantitative result which will may indicate the strength of antibody response and possibly immunity."
RE: Scaredy & Robbo - Yippy Kai Yay13 May 2021 07:33
Enjoyed this excursion yesterday, well done to you both. Let's keep an eye on that LinkedIn account in case anymore test usability days turn up. Hopefully we'll have the news were all waiting for and there won't be a need but no harm keeping an eyeball or two on it.
Good work Vegas, Michael Mena was on Irish TV last night to debate the use of antigen lft against a deeks type doc. The dialog in the media is still very poorly articulated for lft due to poor research lets hope Avctva changes that for the good.
Any guru like pmjh that can search the YouTube video metadata of the kansas university doc videos that have been posted. We got so much info and excitement from them prior to the Activ2 trial that we're probably missing out on real updates from the trial that the docs discuss on their weekly calls.
Easy. Speculation on my part but TT with Avacta has been going on with weeks now. We can produce for them outside of the gov contract and when the gov gives the green light for the sovereign test we use the government loaned equipment for that purpose. They are obviously not sitting around in Alva and the TT is possibly all completed just waiting on the green light. If TT has to be done for whatever test the government goes with then this is extraordinary poor planning at the very basic level and would really defy logic to make an announcement and then say sorry manufacturing is months away as all diagnostics companies now have to TT... All being coordinated behind the scenes let's see what announcements May brings... GLA not far away now...
So we finally have confirmation to the market...( Avacta's RNS this morning).
· On 8 February 2021, we established a commercial partnership with Mologic following several months' collaborative work to provide Avacta with a faster route to market for the lateral flow rapid antigen test by CE marking it for professional use under Mologic's existing ISO13485 quality system. The CE mark will then be transferred to Avacta after it receives ISO13485 accreditation, which is expected in April 2021.
· The collaboration with Mologic also provides initial manufacturing capacity with the benefit of a short set-up time for the lateral flow test with Global Access Diagnostics ('GAD'), in addition to the agreements with BBI Group, Abingdon Health and others, that will provide manufacturing capabilities that can be scaled to several millions of tests per month.
Yeah it was back in Sep when Avacta & Abdx announced a manufacturing partnership for the CV antigen saliva test. Now that we are a listed company an update to the market clarifying that we are still a manufacturing partner would be welcomed. Better again if they clarified that its for the Avacta Antigen test that was clinical validated today.